TY - JOUR
T1 - Liver fat in adults with GH deficiency
T2 - Comparison to matched controls and the effect of GH replacement
AU - Meienberg, Fabian
AU - Yee, Michael
AU - Johnston, Desmond
AU - Cox, Jeremy
AU - Robinson, Stephen
AU - Bell, Jimmy D.
AU - Thomas, E. Louise
AU - Taylor-Robinson, Simon D.
AU - Godsland, Ian
N1 - Publisher Copyright:
© 2016 John Wiley & Sons Ltd.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Context Existing data regarding the association between growth hormone deficiency (GHD) and liver fat content are conflicting. Objective We aimed (i) to assess intrahepatocellular lipid (IHCL) content in hypopituitary adults with GHD compared to matched controls and (ii) to evaluate the effect of growth hormone (GH) replacement on IHCL content. Design Cross-sectional comparison and controlled intervention study. Patients, Participants Cross-sectional comparison: Twenty-two hypopituitary adults with GHD and 44 healthy controls matched for age, BMI, gender and ethnicity. Intervention study: nine GHD patients starting GH replacement (GH Rx group) and nine GHD patients not starting replacement therapy (non-GH Rx group). Intervention Intervention study: GH replacement for 6 months in the GH Rx group, dosage was titrated to achieve normal IGF-1 levels. Main Outcome Measures HCL content determined by proton magnetic resonance spectroscopy (1H MRS). Results Cross-sectional Comparison: There was no difference in IHCL content between GHD patients and healthy controls (1·89% (0·30, 4·03) vs 1·14% (0·22, 2·32); P = 0·2), and the prevalence of patients with hepatic steatosis (IHCL of ≥ 5·56%) was similar in the two groups (22·7% vs 15·9%; chi-square probability = 0·4). Intervention study: The change in IHCL content over 6 months did not differ between the GH Rx group and the non-GH Rx group (-0·63 ± 4·53% vs + 0·11 ± 1·46%; P = 0·6). Conclusions In our study, liver fat content and the prevalence of hepatic steatosis did not differ between hypopituitary adults with GHD and matched controls. In GHD patients, GH replacement had no effect on liver fat content.
AB - Context Existing data regarding the association between growth hormone deficiency (GHD) and liver fat content are conflicting. Objective We aimed (i) to assess intrahepatocellular lipid (IHCL) content in hypopituitary adults with GHD compared to matched controls and (ii) to evaluate the effect of growth hormone (GH) replacement on IHCL content. Design Cross-sectional comparison and controlled intervention study. Patients, Participants Cross-sectional comparison: Twenty-two hypopituitary adults with GHD and 44 healthy controls matched for age, BMI, gender and ethnicity. Intervention study: nine GHD patients starting GH replacement (GH Rx group) and nine GHD patients not starting replacement therapy (non-GH Rx group). Intervention Intervention study: GH replacement for 6 months in the GH Rx group, dosage was titrated to achieve normal IGF-1 levels. Main Outcome Measures HCL content determined by proton magnetic resonance spectroscopy (1H MRS). Results Cross-sectional Comparison: There was no difference in IHCL content between GHD patients and healthy controls (1·89% (0·30, 4·03) vs 1·14% (0·22, 2·32); P = 0·2), and the prevalence of patients with hepatic steatosis (IHCL of ≥ 5·56%) was similar in the two groups (22·7% vs 15·9%; chi-square probability = 0·4). Intervention study: The change in IHCL content over 6 months did not differ between the GH Rx group and the non-GH Rx group (-0·63 ± 4·53% vs + 0·11 ± 1·46%; P = 0·6). Conclusions In our study, liver fat content and the prevalence of hepatic steatosis did not differ between hypopituitary adults with GHD and matched controls. In GHD patients, GH replacement had no effect on liver fat content.
UR - http://www.scopus.com/inward/record.url?scp=84973865981&partnerID=8YFLogxK
U2 - 10.1111/cen.13042
DO - 10.1111/cen.13042
M3 - Article
C2 - 26895949
AN - SCOPUS:84973865981
SN - 0300-0664
VL - 85
SP - 76
EP - 84
JO - Clinical Endocrinology
JF - Clinical Endocrinology
IS - 1
ER -